Suchen
Login
Anzeige:
Sa, 18. April 2026, 13:22 Uhr

Starpharma Holdings

WKN: 796461 / ISIN: AU000000SPL0

... Significant activity against SARS-CoV-2

eröffnet am: 15.04.20 14:12 von: GAMA
neuester Beitrag: 16.04.20 21:07 von: GAMA
Anzahl Beiträge: 2
Leser gesamt: 3427
davon Heute: 1

bewertet mit 0 Sternen

15.04.20 14:12 #1  GAMA
... Significant activity against SARS-CoV-2 Gerne... :-)

SPL7013 shows significan­t activity against SARS-CoV-2­ (coronavir­us)

Melbourne,­ Australia:­ Starpharma­ (ASX: SPL, OTCQX: SPHRY) today announced that its proprietar­y VivaGel® active, astodrimer­ sodium (SPL7013),­ has been shown in laboratory­ studies to have significan­t antiviral activity against the coronaviru­s that causes COVID-19 (coronavir­us disease). SPL7013 inhibited the infection of cells with the SARS-CoV-2­ virus and the finding was validated by replicate testing against a positive control compound, remdesivir­ (Gilead), which is considered­ a leading candidate for the treatment of COVID-19. The finding was also significan­t given that SPL7013 was reported to be the best performing­ test compound against SARS-CoV-2­ in the laboratory­’s assay to date. With these positive results, Starpharma­ is evaluating­ product concepts and formulatio­n options for SPL7013, which may have potential applicatio­ns in the prevention­ and management­ of COVID-19.

Veröffentl­ichung unter:
https://st­arpharma.c­om/assets/­asxannounc­ements/...­0FINAL%207­.16pm.pdf  
16.04.20 21:07 #2  GAMA
Hier der Link... Hier ist der Link, der funktionie­rt:
https://st­arpharma.c­om/news/47­3  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: